Abiopharma

MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) Reports the reporting period Financial Results MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: 32136
• Net Income: 3837
• EPS: Not disclosed
• Cash and equivalents: $4
  • expected ongoing impact of Maravai’s cost structure and operating efficiency initiatives on its EBITDA performance and Maravai’s ability to execute on its strategy to drive sustained, profitable growth, constitute forward-looking statements and are identified by words like “believe,” “expect,” “see,” “project,” “may,” “will,” “should,” “seek,” “anticipate,” or “could” and similar expressions.Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations and assumptions regarding the future of Maravai’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of management’s control. Maravai’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause Maravai’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:•The level of Maravai’s customers’ spending on and demand for TriLink and Cygnus products and services.•Maravai’s operating results are prone to significant fluctuation, which may make Maravai’s future operating results difficult to predict and could cause Maravai’s actual operating results to fall below expectations or any guidance Maravai may provide. •Uncertainty regarding the extent and duration of Maravai’s revenue associated with high-volume sales of CleanCap® for commercial phase vaccine programs and the dependency of such revenue, in important respects, on factors outside our control.•Shifts in the trade, economic and other policies and priorities of the U.S. federal government, on Maravai and Maravai’s customers’ current and future business operations.•Unintended consequences from our recent organizational changes and workforce reduction.•Use of Maravai’s products by customers in the production of vaccines and therapies, some of which represent relatively new and still-developing modes of treatment, and the impact of unforeseen adverse events, negative clinical outcomes, development of alternative therapies, or increased regulatory scrutiny of these modes of treatment and their financial cost on Maravai’s customers’ use of its products and services. •Competition with life science, pharmaceutical and biotechnology companies who are substantially larger than Maravai and potentially capable of developing new approaches that could make Maravai’s products, services and technology obsolete. •The potential failure of Maravai’s products and services to perform as expected and the reliability of the technology on which Maravai’s products and services are based. •Maravai’s use of Artificial Intelligence technologies, including Machine Learning, and business, compliance and reputational challenges that may result from such use.•The risk that Maravai’s products do not comply with required quality standards. •Market acceptance of Maravai’s life science reagents.•Maravai’s ability to efficiently manage its strategic acquisitions and organic growth opportunities.•Natural disasters, geopolitical instability (including ongoing military conflicts) and other catastrophic events. •Risks related to Maravai’s acquisitions, including whether Maravai achieves the anticipated benefits of acquisitions of businesses or technologies. •Product liability lawsuits.•Maravai’s dependency on a limited number of customers for a high percentage of its revenue and Maravai’s ability to maintain its current relationships with such customers. •Maravai’s reliance on a limited number of suppliers or, in some cases, sole suppliers, for some of Maravai’s raw materials and the risk that Maravai may not be able to find replacements or immediately transition to alternative suppliers. •The risk that Maravai’s products become subject to more onerous regulation by the U.S. Food and Drug Administration or other regulatory agencies in the future. •Maravai’s ability to obtain, maintain and enforce sufficient intellectual property protection for Maravai’s current or future products. •The risk that a future cyber-attack or security breach cannot be prevented.•Maravai’s ability to protect the confidentiality of Maravai’s proprietary information.•The risk that one of Maravai’s products may be alleged (or found) to infringe on the intellectual property rights of third parties.•Compliance with Maravai’s obligations under intellectual property license agreements. •Maravai’s or Maravai’s licensors’ failure to maintain the patents or patent applications in-licensed from a third party.•Maravai’s ability to adequately protect Maravai’s intellectual property and proprietary rights throughout the world.•Maravai’s existing level of indebtedness and Maravai’s ability to raise additional capital on favorable terms. •Maravai’s ability to generate sufficient cash flow to service all of Maravai’s indebtedness.•Maravai’s potential failure to meet Maravai’s debt service obligations.•Restrictions on Maravai’s current and future operations under the terms applicable to Maravai’s credit agreement.•Maravai’s dependence, by virtue of Maravai’s principal asset being its interest in Maravai Topco Holdings, LLC (“Topco LLC”), on distributions from Topco LLC to pay Maravai’s taxes and expenses, including payments under a tax receivable agreement with the former owners of Topco LLC (the “Tax Receivable Agreement” or “TRA”) together with various limitations and restrictions that impact Topco LLC’s ability to make such distributions. •The risk that conflicts of interest could arise between Maravai’s shareholders and Maravai Life Sciences Holdings, LLC (“MLSH 1”), the only other member of Topco LLC, and impede business decisions that could benefit Maravai’s shareholders. •The substantial future cash payments Maravai may be required to make under the Tax Receivable Agreement to MLSH 1 and Maravai Life Sciences Holdings 2, LLC (“MLSH 2”), an entity through which certain of Maravai’s former owners hold their interests in the Company and the negative effect of such payments. •The fact that Maravai’s organizational structure, including the TRA, confers certain benefits upon MLSH 1 and MLSH 2 that will not benefit Maravai’s other common shareholders to the same extent as they will benefit MLSH 1 and MLSH 2. •Maravai’s ability to realize all or a portion of the tax benefits that are expected to result from the tax attributes covered by the Tax Receivable Agreement.•The possibility that Maravai will receive distributions from Topco LLC significantly in excess of Maravai’s tax liabilities and obligations to make to make payments under the Tax Receivable Agreement.•Factors that could lead to future impairment of Maravai’s goodwill and other amortizable intangible assets.•Unanticipated changes in effective tax rates or adverse outcomes resulting from examination of Maravai’s income or other tax returns.•Maravai’s ability to design and maintain effective internal control over financial reporting in the future.•The fact that investment entities affiliated with GTCR, LLC currently control a majority of the voting power of Maravai’s outstanding common stock, and it may have interests that conflict with Maravai’s or yours in the future. •Risks related to Maravai’s “controlled company” status within the meaning of the corporate governance standards of NASDAQ. •The potential anti-takeover effects of certain provisions in Maravai’s corporate organizational documents.•Potential sales of a significant portion of Maravai’s outstanding shares of Class A common stock.•Potential preferred stock issuances and the anti-takeover impacts of any such issuances.•Such other factors as discussed throughout the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Maravai’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, as well as other documents Maravai files with the Securities and Exchange Commission.Any forward-looking statements made in this release are based only on information currently available to management and speak only as of the date on which it is made. Maravai undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.Contact Information:Deb HartMaravai LifeSciences+ 1 858-988-5917